← Oncology Approval Tracker

FDA DECISION ·

Cyclophosphamide injection (Nevakar)

cyclophosphamide · Nevakar Injectables

FDA approvalNew formulationMultiple cancer types
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A 200 mg/mL IV solution for labeled adult and pediatric malignancies, including selected lymphomas and leukemias, multiple myeloma, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma and breast carcinoma.

LAMPGEN ANALYSIS

Why it matters

The distinct concentration adds a preparation option for several longstanding oncology indications.

What research teams should watch

Use the product-specific concentration, excipients and dilution procedure when building pharmacy instructions.

PRIMARY RECORDS

Sources